MMR deficiency, specifically loss of mismatch repair proteins such as MLH1, MSH2, MSH3, MLH3, MSH6 and PMS2, can decrease the cytotoxicity of temozolomide treatment in MGMT-deficient cells (6). This evidence concerns the gene MLH3 and hyperinsulinemic hypoglycemia, familial, 4.